|
Home > Archive > HIV Aids > December 2006 > Junk Science Re: Buxus sempervirens data
You are viewing an archived Text-only version of the thread.
To view this thread in it's original format and/or if you want to reply to
this thread please [click here]
| Author |
Junk Science Re: Buxus sempervirens data
|
|
|
|
"GMCarter" <fiar@verizon.net> wrote in message
news:l4c7m2d1tnuvt3huv0bll35a05iknffdik@4ax.com...
> On Tue, 21 Nov 2006 10:56:09 -0600, " Death" <Death@yourdoor.net>
> wrote:
Typical George Mary Carter Junk Science.
Both studies cited are a load of crap - lacking a true study
group versus a placebo group.
Fact remains, all the study participants were on all kinds
of toxic drugs (antivirals, antifungals, antibiotics, etc) - as
well as every other herbal treatment available.
> ***
> Durant J, Chantre Ph, Gonzalez G et al: Efficacy and safety of Buxus
> sempervirens L. preparations (SPV30) in HIV-infected asymptomatic
> patients: a multicentre, randomized, double blind, placebo-controlled
> trial. Phytomedicine 1998; 5(1):1-10.
>
> Described best here:
> www.catie.ca/pdf/supple-e/spv30.pdf
>
> They note: "Those taking SPV30 were less likely to develop symptoms of
> AIDS or AIDS-related illnesses. The results were better for people
> taking the low dose of 990 milligrams of SPV30 per day than for those
> taking 1,980 mg.
>
| |
|
|
"Life" <Life@life.com> wrote in message[vbcol=seagreen]
>
> Typical George Mary Carter Junk Science.
>
much snipped from pdf format, bad spelling not corrected:
Winter 2000
What is it?
SPV30 is derived from the European boxwood tree Buxus sempervirens. It is produced by
Arkopharma, a European company. The company is not willing to say exactly how the
product is produced or from what parts of the plant SPV30 comes from. Arkopharma uses a
freeze-drying process that it calls "cryogrinding" to extract SPV30 from the plant.
Wha What do HIV-positive people use t this supplement for?
l To limit the body's production of HIV
SPV30 may influence the immune system in a way that slows the production of HIV. Most
of our immune cells are in a latent or restinstate most of the time. However, when the
immune system recognizes that the body has been invaded by a micro-organism, like HIV,
immune cells that guard against this particular infection are activated. HIV can only infect
cells when they are in this activated state. HIV can also only use the cell to produce more
copies of the virus when the cell is in an activated state. When a cell produces more
copies of the virus, the presence of more virus activates more cells. These activated cells
are,
in turn, vulnerable to infection. This vicious cycle allows HIV to perpetuate itself among
the very cells that would normally defend the body.
Internal studies by the makers of SPV30 suggest that this treatment suppresses the
production of activated cells, leaving few cell vulnerable to infection. To date, these studies
have not been published by the peer-reviewe medical press. Additional studies done by the
company also suggest that SPV30 slows the production of HIV in test-tube studies. Again
the data from these studies are not available to the public.
A small placebo-controlled trial of SPV30 was done in the early 1990s. Documents offered by
Arkopharma suggest that the people living with HIV (PHAs) in this study experienced an
average increase of about 100 CD4+ cells after 30 weeks of treatment. Again, these results
have never been published in the peer-reviewed medical press. Based on this study, the
company offered SPV30 free of charge to 400 America PHAs in the mid-1990s. There was no
control arm for this study, and the fact that people knew they were testing SPV30 may
have influenced the results. Data from 173 subjects were presented at the 1996
International AIDS Conference in Vancouver.
It suggested that people using the treatment over a six-month period saw modest decreases
in viral load (more than 0.3 log in 38 per cent of the people) and slight increases in CD4+
counts (41 per cent of people had increases; the median change was 8.5 per cent or five cells).
These differences are small and could be due to chance alone since they are within the range of
variation usually seen with CD4+ and viral load tests. People in the study also reported
feeling better and more energized. As well, an improvement in existing skin conditions was
noted in some people.
A placebo-controlled study of HIV-positive people taking SPV30 was published in 1998.
People in this study did not take any other antiretrovirals or immunomodulators; each had....
| |
|
|
" Death" <Death@yourdoor.net> wrote in message
news:W_19h.4962$k6.4418@bignews8.bellsouth.net...
>
> "Life" <Life@life.com> wrote in message
>
> Internal studies by the makers of SPV30 suggest that this treatment
> suppresses the
> production of activated cells, leaving few cell vulnerable to infection.
Sure - that's what cancer-treatment immunosuppressives do - when the immune
system cell is activated, the drugs suppress it. For a disease of immune
suppression,
this is probably not a good thing to do - suppress the immunity further.
|
| |
|
|